| Company Name: |
Hubei Yangxin Medical Technology Co., Ltd.
|
| Tel: |
15374522761 |
| Email: |
3003392093@qq.com |
| Products Intro: |
Product Name:Selexipag Metabolite-d6 (ACT-333679-d6)
CAS:1265295-56-4
Purity:99%+ HPLC Package:10mg;25mg;50mg;100mg
|
| Company Name: |
Shanghai isotope chemical co.,ltd
|
| Tel: |
021-51600108 13062666369 |
| Email: |
sales@isotopechem.com |
| Products Intro: |
Product Name:Selexipag Metabolite-d6 (ACT-333679-d6)
CAS:1265295-56-4
Purity:1mg Package:1mg Remarks:RMCS16019-1mg
|
| Company Name: |
Nanjing Shizhou Biology Technology Co.,Ltd
|
| Tel: |
17301488900 |
| Email: |
judy.xia@synzest.com |
| Products Intro: |
Product Name:Selexipag metabolite ACT-333679 D7
CAS:1265295-56-4
Purity:98% Package:1mg;5mg;10mg;100mg
|
| Company Name: |
CLEARSYNTH LABS LTD.
|
| Tel: |
+91-22-45045900 |
| Email: |
sales@clearsynth.com |
| Products Intro: |
Product Name:Selexipag metabolite ACT-333679 D6
CAS:1265295-56-4
|
|
| | Selexipag Metabolite-d6 (ACT-333679-d6) Basic information |
| | Selexipag Metabolite-d6 (ACT-333679-d6) Chemical Properties |
| | Selexipag Metabolite-d6 (ACT-333679-d6) Usage And Synthesis |
| Uses | MRE-269-d6 is deuterium labeled MRE-269. MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Fuchikami C, et al. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcin DOI:10.1016/j.ejphar.2016.11.057
[3] Orie NN, et al. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins. Prostaglandins Other Lipid Mediat. 2013 Oct;106:1-7 DOI:10.1016/j.prostaglandins.2013.07.003
[4] Kuwano K, et al. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses DOI:10.1124/jpet.108.138305 |
| | Selexipag Metabolite-d6 (ACT-333679-d6) Preparation Products And Raw materials |
|